Alaunos Therapeutics (TCRT) Total Current Liabilities (2016 - 2025)
Alaunos Therapeutics (TCRT) has disclosed Total Current Liabilities for 15 consecutive years, with $921000.0 as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Total Current Liabilities rose 11.5% year-over-year to $921000.0, compared with a TTM value of $921000.0 through Sep 2025, up 11.5%, and an annual FY2024 reading of $692000.0, down 64.62% over the prior year.
- Total Current Liabilities was $921000.0 for Q3 2025 at Alaunos Therapeutics, down from $1.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $32.9 million in Q3 2022 and bottomed at $692000.0 in Q4 2024.
- Average Total Current Liabilities over 5 years is $11.4 million, with a median of $5.1 million recorded in 2023.
- The sharpest move saw Total Current Liabilities skyrocketed 96.98% in 2022, then crashed 92.73% in 2024.
- Year by year, Total Current Liabilities stood at $16.0 million in 2021, then surged by 50.65% to $24.2 million in 2022, then plummeted by 91.91% to $2.0 million in 2023, then plummeted by 64.62% to $692000.0 in 2024, then skyrocketed by 33.09% to $921000.0 in 2025.
- Business Quant data shows Total Current Liabilities for TCRT at $921000.0 in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.